{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T02:39:01Z","timestamp":1787971141712,"version":"build-2784847793"},"reference-count":39,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T00:00:00Z","timestamp":1715558400000},"content-version":"vor","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.rpth.2024.102444","type":"journal-article","created":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T14:35:10Z","timestamp":1715956510000},"page":"102444","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Safety and efficacy of danazol in immune thrombocytopenia: a systematic review"],"prefix":"10.1016","volume":"8","author":[{"given":"Sangam","family":"Shah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rukesh","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8203-3329","authenticated-orcid":false,"given":"Abhinav","family":"Bhattarai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna","family":"Dahal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunraj","family":"Tharu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandesh","family":"Gautam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laba","family":"Rawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangharsha","family":"Thapa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjit Kumar","family":"Sah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumit","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna","family":"Gundabolu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2024.102444_bib1","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMct1014202","article-title":"Thrombopoietin-receptor agonists for primary immune thrombocytopenia","volume":"365","author":"Imbach","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102444_bib2","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group","volume":"113","author":"Rodeghiero","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102444_bib3","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2015-07-659656","article-title":"High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial","volume":"127","author":"Wei","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102444_bib4","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1056\/NEJMoa030254","article-title":"Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone","volume":"349","author":"Cheng","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102444_bib5","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1182\/blood-2004-03-1168","article-title":"Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications","volume":"104","author":"Kojouri","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102444_bib6","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJMe1009141","article-title":"Management of immune thrombocytopenia\u2014something old, something new","volume":"363","author":"George","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102444_bib7","doi-asserted-by":"crossref","first-page":"546","DOI":"10.7326\/0003-4819-151-8-200910200-00008","article-title":"Risk for hospital contact with infection in patients with splenectomy: a population-based cohort study","volume":"151","author":"Thomsen","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rpth.2024.102444_bib8","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2024.102444_bib9","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ajh.25125","article-title":"Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials","volume":"93","author":"Bussel","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.rpth.2024.102444_bib10","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1182\/blood-2014-06-582346","article-title":"Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients","volume":"124","author":"Khellaf","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102444_bib11","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/bjh.12260","article-title":"Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy","volume":"161","author":"Kuter","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2024.102444_bib12","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","article-title":"Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project","volume":"113","author":"Carson","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102444_bib14","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJM198702263160903","article-title":"Effect of danazol in immune thrombocytopenic purpura","volume":"316","author":"Schreiber","year":"1987","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102444_bib15","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.amjmed.2003.12.024","article-title":"Danazol therapy in patients with chronic idiopathic thrombocytopenic purpura: long-term results","volume":"116","author":"Maloisel","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.rpth.2024.102444_bib16","first-page":"143","article-title":"The role of danazol in the treatment of refractory idiopathic thrombocytopenic purpura. A report of 22 cases","volume":"32","author":"Fenaux","year":"1990","journal-title":"Nouv Rev Fr Hematol (1978)"},{"key":"10.1016\/j.rpth.2024.102444_bib17","doi-asserted-by":"crossref","first-page":"841","DOI":"10.2165\/00002512-200320110-00005","article-title":"Idiopathic thrombocytopenic purpura: a retrospective analysis in 139 patients of the influence of age on the response to corticosteroids, splenectomy and danazol","volume":"20","author":"Andr\u00e8s","year":"2003","journal-title":"Drugs Aging"},{"key":"10.1016\/j.rpth.2024.102444_bib13","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJM198306093082306","article-title":"Danazol for the treatment of idiopathic thrombocytopenic purpura","volume":"308","author":"Ahn","year":"1983","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102444_bib18","doi-asserted-by":"crossref","first-page":"e487","DOI":"10.1016\/S2352-3026(17)30170-9","article-title":"Oral all-trans retinoic acid plus danazol versus danazol as second-line treatment in adults with primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial","volume":"4","author":"Feng","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.rpth.2024.102444_bib19","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1177\/1076029615622002","article-title":"The effect of danazol in primary immune thrombocytopenia: an analysis of a large cohort from a single center in China","volume":"22","author":"Liu","year":"2016","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.rpth.2024.102444_bib20","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1136\/pgmj.66.780.827","article-title":"Danazol in non-splenectomized patients with refractory idiopathic thrombocytopenic purpura","volume":"66","author":"Edelmann","year":"1990","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.rpth.2024.102444_bib21","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/00000441-198910000-00002","article-title":"Very low dose danazol in idiopathic thrombocytopenic purpura and its role as an immune modulator","volume":"298","author":"Mylvaganam","year":"1989","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.rpth.2024.102444_bib22","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000206176","article-title":"Danazol for the treatment of idiopathic thrombocytopenic purpura","volume":"74","author":"Buelli","year":"1985","journal-title":"Acta Haematol"},{"key":"10.1016\/j.rpth.2024.102444_bib23","first-page":"768","article-title":"Danazol in chronic idiopathic thrombocytopenic purpura resistant to corticosteroids","volume":"114","author":"Kotlarek-Haus","year":"1987","journal-title":"Folia Haematol Int Mag Klin Morphol Blutforsch"},{"key":"10.1016\/j.rpth.2024.102444_bib24","first-page":"275","article-title":"Therapeutic effect of danazol on metrorrhagia in patients with idiopathic thrombocytopenic purpura (ITP)","volume":"28","author":"Ambr\u00edz","year":"1986","journal-title":"Nouv Rev Fr Hematol (1978)"},{"key":"10.1016\/j.rpth.2024.102444_bib25","first-page":"293","article-title":"Danazol therapy in idiopathic thrombocytopenic purpura: the efficacy of low-medium dose therapy","volume":"55","author":"Kondo","year":"1992","journal-title":"Int J Hematol"},{"key":"10.1016\/j.rpth.2024.102444_bib26","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000206184","article-title":"Danazol in idiopathic thrombocytopenic purpura","volume":"74","author":"Almagro","year":"1985","journal-title":"Acta Haematol"},{"key":"10.1016\/j.rpth.2024.102444_bib27","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000205948","article-title":"Danazol therapy in refractory chronic immune thrombocytopenic purpura","volume":"77","author":"Mazzucconi","year":"1987","journal-title":"Acta Haematol"},{"key":"10.1016\/j.rpth.2024.102444_bib28","doi-asserted-by":"crossref","first-page":"723","DOI":"10.7326\/0003-4819-111-9-723","article-title":"Long-term danazol therapy in autoimmune thrombocytopenia: unmaintained remission and age-dependent response in women","volume":"111","author":"Ahn","year":"1989","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rpth.2024.102444_bib29","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1365-2141.1985.tb04070.x","article-title":"The use of danazol in the management of chronic immune thrombocytopenic purpura","volume":"61","author":"McVerry","year":"1985","journal-title":"Br J Haematol"},{"issue":"6 Suppl 2","key":"10.1016\/j.rpth.2024.102444_bib40","first-page":"29","article-title":"Treatment of idiopathic thrombocytopenic purpura (ITP) in patients with refractoriness to or with contraindication for corticosteroids and\/or splenectomy with immunosuppressive therapy and danazol","volume":"78","author":"Schiavotto","year":"1993","journal-title":"Haematologica"},{"key":"10.1016\/j.rpth.2024.102444_bib30","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1056\/NEJMoa2100596","article-title":"Mycophenolate mofetil for first-line treatment of immune thrombocytopenia","volume":"385","author":"Bradbury","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2024.102444_bib31","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1182\/blood-2008-04-150078","article-title":"Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP","volume":"113","author":"Bussel","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102444_bib32","doi-asserted-by":"crossref","first-page":"4338","DOI":"10.1182\/blood-2011-03-340166","article-title":"Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program","volume":"118","author":"Khellaf","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2024.102444_bib33","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0140-6736(08)60203-2","article-title":"Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial","volume":"371","author":"Kuter","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.rpth.2024.102444_bib35","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7326\/0003-4819-146-1-200701020-00006","article-title":"Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura","volume":"146","author":"Arnold","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rpth.2024.102444_bib36","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1053\/j.ajkd.2021.06.016","article-title":"ANCA-associated vasculitis following Pfizer-BioNTech COVID-19 vaccine","volume":"78","author":"Shakoor","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.rpth.2024.102444_bib37","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/0002-9378(81)90611-6","article-title":"Danazol: endocrine pharmacology and therapeutic applications","volume":"141","author":"Barbieri","year":"1981","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.rpth.2024.102444_bib38","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/S0168-8278(98)80140-2","article-title":"Danazol therapy: an unusual aetiology of hepatocellular carcinoma","volume":"29","author":"Crampon","year":"1998","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.rpth.2024.102444_bib39","doi-asserted-by":"crossref","first-page":"272","DOI":"10.2340\/00015555-0057","article-title":"Hepatocellular focal nodular hyperplasia after danazol treatment for hereditary angio-oedema","volume":"86","author":"Helsing","year":"2006","journal-title":"Acta Derm Venereol"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S247503792400133X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S247503792400133X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T01:33:08Z","timestamp":1722130388000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S247503792400133X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S247503792400133X"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2024.102444","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of danazol in immune thrombocytopenia: a systematic review","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2024.102444","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"102444"}}